Allergan completes Oculeve acquisition

Wednesday, August 12, 2015

Allergan, a Dublin-based global pharmaceutical company, has completed the acquisition of Oculeve, a development-stage medical device company focused on developing novel treatments for dry-eye disease. Allergan acquired Oculeve for a $125 million upfront payment and commercialization milestone payments related to Oculeve’s lead development program, OD-01. The agreement also includes the acquisition of an additional earlier-stage dry-eye device development program.

[Read More]